An open label, single arm, prospective phase II study to evaluate the efficacy and safety of bevacizumab with gemcitabine and carboplatin as first-line treatment for metastatic triple negative breast cancer patients.

Gupta, Sudeep; K Babu, Govind; Titus Chacko, Raju; Chandra Doval, Dinesh; Desai, Chirag; Kilara, Nalini; Nag, Shona; Shah, Chirag; V. S. Deo, S.; Koppikar, Smruti; Swarup, Binay; Kukreja, Anil; Raina, Vinod

doi:10.1200/jco.2018.36.15_suppl.1098

Public

An open label, single arm, prospective phase II study to evaluate the efficacy and safety of bevacizumab with gemcitabine and carboplatin as first-line treatment for metastatic triple negative breast cancer patients.

Published in Journal of Clinical Oncology • May 20, 2018

Authors:

Sudeep Gupta

Govind K Babu

Raju Titus Chacko

Abstract

1098 Background: There is a higher burden (29.2%-46%) of TNBC patients in India. This single arm, phase II trial evaluated the efficacy and safety of bevacizumab in combination with gemcitabine and carboplatin as first line treatment in Indian patients with metastatic TNBC. Methods: TNBC patients wi...

Subject

Medicine

Bevacizumab

Carboplatin

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!